Literature DB >> 29487949

[Watchful waiting and active surveillance of small renal masses].

R Mager1, S Frees2, A Haferkamp2.   

Abstract

The incidence of small renal masses ≤4 cm is increasing due to the widespread use of cross-sectional imaging. The majority of these represent indolent forms, but the risk for developing metastases is reported in up to 6% of patients. Particularly in old and comorbid patients surgery might be harmful overtreatment. Thus, there is an increasing demand to establish oncologically safe active surveillance protocols. Radiographic or biopsy-based biological markers to appropriately designate candidates for active surveillance are currently the focus of research.

Entities:  

Keywords:  Biomarkers; Biopsy; Mutations; Neoplasm metastasis; Renal cell carcinoma

Mesh:

Year:  2018        PMID: 29487949     DOI: 10.1007/s00120-018-0584-8

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  47 in total

1.  Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.

Authors:  Tobias Klatte; David B Seligson; Jeffrey LaRochelle; Brian Shuch; Jonathan W Said; Stephen B Riggs; Nazy Zomorodian; Fairooz F Kabbinavar; Allan J Pantuck; Arie S Belldegrun
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-24       Impact factor: 4.254

2.  Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.

Authors:  Richard W Joseph; Payal Kapur; Daniel J Serie; Jeanette E Eckel-Passow; Mansi Parasramka; Thai Ho; John C Cheville; Eugene Frenkel; Dinesh Rakheja; James Brugarolas; Alexander Parker
Journal:  Cancer       Date:  2013-12-30       Impact factor: 6.860

3.  Rising incidence of small renal masses: a need to reassess treatment effect.

Authors:  John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

4.  BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma.

Authors:  Payal Kapur; Alana Christie; Jay D Raman; Matthew T Then; Philipp Nuhn; Alexander Buchner; Patrick Bastian; Christian Seitz; Shahrokh F Shariat; Karim Bensalah; Nathalie Rioux-Leclercq; Xian-Jin Xie; Yair Lotan; Vitaly Margulis; James Brugarolas
Journal:  J Urol       Date:  2013-09-25       Impact factor: 7.450

5.  Treatment management of small renal masses in the 21st century: a paradigm shift.

Authors:  Maxine Sun; Firas Abdollah; Marco Bianchi; Quoc-Dien Trinh; Claudio Jeldres; Rodolphe Thuret; Zhe Tian; Shahrokh F Shariat; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz
Journal:  Ann Surg Oncol       Date:  2012-02-10       Impact factor: 5.344

6.  Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.

Authors:  A Ari Hakimi; Ying-Bei Chen; James Wren; Mithat Gonen; Omar Abdel-Wahab; Adriana Heguy; Han Liu; Shugaku Takeda; Satish K Tickoo; Victor E Reuter; Martin H Voss; Robert J Motzer; Jonathan A Coleman; Emily H Cheng; Paul Russo; James J Hsieh
Journal:  Eur Urol       Date:  2012-09-27       Impact factor: 20.096

Review 7.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

8.  Multiple growth periods predict unfavourable pathology in patients with small renal masses.

Authors:  Alex Jang; Hiten D Patel; Mark Riffon; Michael A Gorin; Alice Semerjian; Michael H Johnson; Mohamad E Allaf; Phillip M Pierorazio
Journal:  BJU Int       Date:  2017-11-01       Impact factor: 5.588

9.  Age, Gender and R.E.N.A.L. Nephrometry Score do not Improve the Accuracy of a Risk Stratification Algorithm Based on Biopsy and Mass Size for Assigning Surveillance versus Treatment of Renal Tumors.

Authors:  Takahiro Osawa; Khaled S Hafez; David C Miller; Jeffrey S Montgomery; Todd M Morgan; Ganesh S Palapattu; Alon Z Weizer; Elaine M Caoili; James H Ellis; Lakshmi P Kunju; J Stuart Wolf
Journal:  J Urol       Date:  2015-10-30       Impact factor: 7.450

10.  BAP1 loss defines a new class of renal cell carcinoma.

Authors:  Samuel Peña-Llopis; Silvia Vega-Rubín-de-Celis; Arnold Liao; Nan Leng; Andrea Pavía-Jiménez; Shanshan Wang; Toshinari Yamasaki; Leah Zhrebker; Sharanya Sivanand; Patrick Spence; Lisa Kinch; Tina Hambuch; Suneer Jain; Yair Lotan; Vitaly Margulis; Arthur I Sagalowsky; Pia Banerji Summerour; Wareef Kabbani; S W Wendy Wong; Nick Grishin; Marc Laurent; Xian-Jin Xie; Christian D Haudenschild; Mark T Ross; David R Bentley; Payal Kapur; James Brugarolas
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

View more
  1 in total

1.  [Small renal cell carcinoma-active surveillance and ablation].

Authors:  J J Wendler; R Damm; U-B Liehr; T Brunner; M Pech; M Schostak
Journal:  Urologe A       Date:  2018-06       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.